248 related articles for article (PubMed ID: 23231880)
1. Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone.
Manu P; Correll CU; Wampers M; van Winkel R; Yu W; Shiffeldrim D; Kane JM; De Hert M
Schizophr Res; 2013 Feb; 143(2-3):358-62. PubMed ID: 23231880
[TBL] [Abstract][Full Text] [Related]
2. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
Atmaca M; Kuloglu M; Tezcan E; Ustundag B
J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
[TBL] [Abstract][Full Text] [Related]
3. The effects of novel antipsychotics on glucose and lipid levels.
Wirshing DA; Boyd JA; Meng LR; Ballon JS; Marder SR; Wirshing WC
J Clin Psychiatry; 2002 Oct; 63(10):856-65. PubMed ID: 12416594
[TBL] [Abstract][Full Text] [Related]
4. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Rummel-Kluge C; Komossa K; Schwarz S; Hunger H; Schmid F; Lobos CA; Kissling W; Davis JM; Leucht S
Schizophr Res; 2010 Nov; 123(2-3):225-33. PubMed ID: 20692814
[TBL] [Abstract][Full Text] [Related]
5. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
[TBL] [Abstract][Full Text] [Related]
6. Nocturnal enuresis in patients taking clozapine, risperidone, olanzapine and quetiapine: comparative cohort study.
Harrison-Woolrych M; Skegg K; Ashton J; Herbison P; Skegg DC
Br J Psychiatry; 2011 Aug; 199(2):140-4. PubMed ID: 21653944
[TBL] [Abstract][Full Text] [Related]
7. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.
Newcomer JW; Ratner RE; Eriksson JW; Emsley R; Meulien D; Miller F; Leonova-Edlund J; Leong RW; Brecher M
J Clin Psychiatry; 2009 Apr; 70(4):487-99. PubMed ID: 19358783
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
9. Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.
Kelly DL; Kreyenbuhl J; Love RC; Van-Duong Q; Conley RR
J Clin Psychiatry; 2003 Sep; 64(9):1133-4. PubMed ID: 14628994
[No Abstract] [Full Text] [Related]
10. Atypical antipsychotics and dopamine D(1) receptor agonism: an in vivo experimental study using core temperature measurements in the rat.
Oerther S; Ahlenius S
J Pharmacol Exp Ther; 2000 Feb; 292(2):731-6. PubMed ID: 10640312
[TBL] [Abstract][Full Text] [Related]
11. A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine.
Sumiyoshi T; Roy A; Anil AE; Jayathilake K; Ertugrul A; Meltzer HY
J Clin Psychopharmacol; 2004 Jun; 24(3):345-8. PubMed ID: 15118492
[No Abstract] [Full Text] [Related]
12. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
van Winkel R; De Hert M; Wampers M; Van Eyck D; Hanssens L; Scheen A; Peuskens J
J Clin Psychiatry; 2008 Mar; 69(3):472-9. PubMed ID: 18348593
[TBL] [Abstract][Full Text] [Related]
13. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
Sernyak MJ; Leslie DL; Alarcon RD; Losonczy MF; Rosenheck R
Am J Psychiatry; 2002 Apr; 159(4):561-6. PubMed ID: 11925293
[TBL] [Abstract][Full Text] [Related]
14. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients.
Citrome L; Jaffe A; Levine J; Allingham B; Robinson J
Psychiatr Serv; 2004 Sep; 55(9):1006-13. PubMed ID: 15345760
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.
Gianfrancesco FD; Grogg AL; Mahmoud RA; Wang RH; Nasrallah HA
J Clin Psychiatry; 2002 Oct; 63(10):920-30. PubMed ID: 12416602
[TBL] [Abstract][Full Text] [Related]
16. Quetiapine treatment in youth is associated with decreased insulin secretion.
Ngai YF; Sabatini P; Nguyen D; Davidson J; Chanoine JP; Devlin AM; Lynn FC; Panagiotopoulos C
J Clin Psychopharmacol; 2014 Jun; 34(3):359-64. PubMed ID: 24633003
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia.
Karagianis J; Williams R; Davis L; Procyshyn R; Monga N; Hanley J; Chandrasena R; Thakur A; Dickson R
Curr Med Res Opin; 2009 Sep; 25(9):2121-32. PubMed ID: 19601707
[TBL] [Abstract][Full Text] [Related]
18. TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment.
Huang HH; Wang YC; Wu CL; Hong CJ; Bai YM; Tsai SJ; Liou YJ
Neurosci Lett; 2011 Oct; 504(3):277-80. PubMed ID: 21967963
[TBL] [Abstract][Full Text] [Related]
19. Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine.
Yasui-Furukori N; Sato Y; Furukori H; Saito M; Nakagami T; Kaneko S
J Clin Psychiatry; 2009 Jan; 70(1):95-100. PubMed ID: 19026267
[TBL] [Abstract][Full Text] [Related]
20. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
